Investigating the immunotoxic potential of candidate drugs as part of a preclinical safety evaluation poses several problems. These include the need for practical, validated tests, the difficulty in establishing the toxicologic significance of positive findings, and a poor understanding of the predictive value such findings hold for drug effects in man. A key component of this investigation is the toxicologic profile generated through preclinical toxicity and safety studies. As this "routine" assessment becomes increasingly comprehensive and sophisticated, most toxicologically significant drug-associated effects are revealed. Such findings may serve as "triggers" for investigating possible immune mechanisms. Decisions to test specifically for immunotoxicity may also be influenced by the molecular structure and pharmacologic profile of the compound, as well as the intended use of the drug. Examples of such indications and follow-up studies are discussed in this review. We are presently poorly equipped to effectively screen drugs indiscriminately for an immunotoxic potential. We are better prepared, however, to investigate whether a drug-associated change is due to an adverse effect on the immune system. This problem-oriented approach to immunotoxicology challenges us as diagnosticians and immunopathologists, and requires a close working relationship among the toxicologic pathologist, the basic immunologist, the immunopharmacologist, and the clinician.
INTRODUCTION
The purpose of this paper is to discuss the role of a conventional preclinical safety assessment program in evaluating the immunotoxic potential of xenobiotics in the pharmaceutical industry, as we are less familiar with the practical problems and critical issues pertaining to immunotoxicology within the chemical and cosmetic industries. It is clear, however, that the development process differs substantially among these sectors of industry; consequently, so do the issues concerning this controversial area. Some of these important differences will be addressed later in this discussion. Not surprisingly, organizations within the pharmaceutical industry also differ regarding the philosophy of toxicity and safety testing, specifically with regard to evaluating the immunotoxic potential of candidate compounds.
We will first review these general approaches and comment on some of the practical problems they present to the pharmaceutical industry. We will then discuss what a conventional preclinical safety eval- uation program contributes, in our view, to an immunotoxicologic evaluation.
APPROACHES TO TESTING FOR IMMUNOTOXICITY
It is increasingly evident that whetlier preclinical research and development organizations should be concerned about the immunotoxic potential of candidate drugs is no longer an issue in the pharmaceutical industry. At issue today is how and wltert this concern should be addressed in a drug development program, and whether specific testing for drug effects on the immune system should be routinely employed. In this regard, there have been two approaches leading to the decision of whether or not to test specifically for effects on the immune system. These are summarized by the following questions: 1) Does a drug or chemical possess the potential to exert an adverse effect on the immune system? 2) Is a drug-or chemical-induced toxicity due to an adverse effect on the immune system?
The first approach implies the screening of compounds, using a battery of tests for immune function, host resistance and immune-mediated disease, when nothing adverse has yet been demonstrated. The second implies a problem-driven system with indications for specific testing for immunotoxicity 283 TOXICOLOGIC PATHOLOGY derived from the toxicologic profile of the candidate drug, as generated using conventional safety and toxicity studies.
The first approach has been widely advocated, particularly within the chemical industry. However, many of the legitimate concerns raised by scientists within that industry, regarding the immunotoxic potential of chemicals under development, are less applicable to the pharmaceutical industry for several reasons: 1) there is usually substantially less safety and toxicity data, and far less information on pharmacology and metabolism, available on which to base a risk assessment; 2) clinical trials examining safety and efficacy are generally not performed;' 3) there is generally less post-marketing surveillance of adverse reactions in man; 4) exposure to man is often less restricted; and perhaps for these reasons, 5 ) there is greater precedent for chemicals being marketed or released into the environment that are immunotoxic in man (3, 44, 63).
Screening for effects on the immune system poses several problems. Our understanding of the immune system, as a whole, is more limited than that of other target organ systems. This reflects more the heterogeneity and complexity of that system than our knowledge of immunobiology. We have a much clearer understanding, for example, of the important factors influencing glomerular filtration rate than those affecting cell-mediated immunity. Secondly, the end points of toxicity (and the "no effect dose") in other organ systems are more often identifiable and quantifiable by a single parameter or a small number of test results. Despite the wealth of experience with assays for immune function within the experimental immunology laboratory, many of these tests have not been validated regarding sensitivity, specificity and predictive value for adverse drug effects iiz v i m This is also true with other tests employed in investigative toxicology; it becomes an important issue, however, when the tests are used to screen compounds and the results are interpreted in isolation, without a full understanding of the pharmacology, drug metabolism and toxicologic profile of that compound in the animal model employed.
A third problem inherent in screening for effects on the immune system is the need to establish the toxicologic significance of the findings. It is this obligation that distinguishes the immunopharmacologist from the immunotoxicologist in pharmaceutical research and development organizations. Additional information, besides that obtained by random screening, is usually required to establish the biologic or toxicologic significance of changes in parameters of immune function, and major decisions based solely on such findings are, at best, precarious. Yet the critical mass of data required to be diagnostic or predictive of significant drug-induced immune dysfunction remains poorly defined.
The second approach to testing for immunotoxicity uses specific assays for immune function or immune-mediated disease, not to assess the overall status of the immune system, but to investigate the pathogenesis of immune dysfunction expressed during the course of routine toxicity and safety studies. Although fishing expeditions are sometimes indicated, where several aspects of immune function are examined, tests for adverse effects on the immune system are usually used more selectively, and the results interpreted in the context of the complete toxicologic profile. Indications in a problem-driven system, both for surveying broadly for immune dysfunction and for more focused investigations, will be discussed in the next section.
CONTRIBUTIONS OF "ROUTINE" SAFETY AND

TOXICITY TESTING
What constitutes "routine" testing varies significantly within the pharmaceutical industry. In this discussion, we will assume that it includes a series of acute, subacute, and chronic toxicity studies, usually performed in at least two species of laboratory animals. Teratology and reproductive toxicology (segments I, I1 and 111) studies are generally also performed, as are long-term carcinogenicity studies. In general, these studies include interim clinical evaluations, the monitoring of weight gain and food consumption, interim and terminal laboratory monitoring (hematology, clinical chemistry, urinalysis) and a complete gross and microscopic evaluation of tissues upon completion of the studies. We will make two additional critical assumptions: 1) the design and interpretation of these studies are influenced by a broad foundation of data relevant to the candidate drug, including chemistry (structure-function relationships), molecular and cell biology, pharmacology, drug metabolism and available clinical information on related drugs in man; and 2) any toxicity or positive finding is fully defined or investigated (employing state-of-the-art technology and expertise in investigative toxicology and experimental pathology), in close collaboration with other research and development scientists.
What we have described is the ideal, and more often than we would like, we must evaluate the toxic potential of candidate drugs without some of the aforementioned information. Based on these assumptions, however, the role of conventional pathology and toxicology in the assessment of the immunotoxic potential of candidate drugs is two-fold: 1) to detect toxic effects due to drug-induced changes in immunc function and provide indications for studies designed to confirm and more fully define the toxicologic mechanism, 2) to provide other information useful in assessing the biologic or toxicologic significance of changes in laboratory parameters of immune function.
At this juncture it is appropriate to consider what types of offending compounds testing systems should be designed to detect. Compounds designed to be cytotoxic, such as anti-cancer drugs, would presumably not be of concern, as immunotoxicity would be anticipated (64) . Also of little concern would be compounds whose immunotoxic potential is irrelevant in the context of normal clinical practice and definition of safety. For example, potent nephrotoxins, by inducing severe or chronic azotemia, may be immunosuppressive (36) . This indirect action need not be fully defined by our testing systems. At the other extreme, the subtle immunomodulating properties of a compound such as cimetidine (38, 54), which have little or no toxicologic significance, need not necessarily be detected by routine toxicity and safety studies. While this information is arguably desirable, it is not necessary in making decisions regarding safety. The objective should be to have routine testing systems that identify candidate drugs whose immunotoxic potential falls somewhere between these extremes. Many of the substances currently under development in the pharmaceutical industry, such as peptides, monoclonal antibodies, H,-receptor antagonists, prostaglandins, nonsteroidal/anti-inflammatory drugs, steroidal hormones, neuroendocrinological agents and retinoids, among others show this potential (31) . We agree with this perspective and the principle that the pharmaceutical industry is obligated to detect and fully define this important toxic potential of the drugs we develop.
Although adverse effects on the immune system have been arbitrarily divided into three categories (immunosuppression, autoimmune disorders, and hypersensitivity), it is now clear that iatrogenic reactions with immunological mechanisms may be further subdivided (12) . As knowledge of the immune system expands, these distinctions become increasingly blurred. For example, immunosuppressive drugs that suppress suppressor-cell activity can induce autoimmune disease (27) . Moreover, some agents can cause immunosuppression or immunostimulation, depending on the dose or duration of exposure (55, 64).
Routine testing systems are limited in their ability to define immunosuppressive drug actions. Some important effector mechanisms, such as blood neutrophils, are monitored directly (although, in this case, only quantitative changes are detected). Other approaches routinely applied include histology and cytology of primary (bone marrow, thymus) and secondary (spleen, lymph nodes, gut-associated lymphoid tissue) lymphoid organs. Although changes in cellularity and cell distribution in these organs (e.g., T-and B-cell dependent areas of lymph nodes) can reflect immunosuppressive events (29), they are relatively crude and insensitive barometers of immune status (6 1). This may change with the application and growing accessibility to reagents and technology providing morphometric analysis and immunofluorescent (flow cytometry), immunocytochemical and enzyme-histochemical stains for specific subpopulations of immunocytes. The latter techniques, although well within the armamentarium of the experimental pathologist, are not regarded today as routine.
Routine test systems are well-designed, however, to detect the coitsequeirces of immunosuppression and the conditions often associated with it. Widespread effects on rapidly dividing tissue (bone marrow, intestine, gonads) would exemplify such a change. Experimental animals in preclinical toxicity studies are carefully monitored using clinicopathologic tests designed to detect infection and neoplasia.
For example, a dose-dependent incidence of a viral or bacterial infection is an important indication for further investigation of drug effects on host resistance. The pharmacologic profile of the compound, type and distribution of the infection, and tissue response may all suggest possible mechanisms to explore. Increasingly, clinicopathologic surveys are being applied in reproductive toxicity trials, acknowledging the fact that the most profound effects of compounds which interfere with the immune response occur during ontogenesis of the lymphoid system (5 1, 60).
Similarly, inflammatory or tissue-destructive disorders consistent with an immune-mediated pathogenesis (immune cytopenia, vasculitis, glomerulonephritis, amyloidosis, etc.) have well-established clinical and laboratory manifestations in our animal models, which can be detected, studied and defined. The diagnostic expertise and technology in immunopathology employed in the pharmaceutical industry is on a par with that of our counterparts in the human clinical setting. Significantly, these resources are applied under more tightly controlled conditions, often resulting in better definition of the disorder than can be achieved by our colleagues in the clinic. Examples of such findings will be presented later in this discussion. It is not the purpose of this paper to review the immunopathology of, or diagnostic approaches to, these disorders. We refer the reader to reviews on these subjects (49, 53, 58,
65).
Hypersensitivity, or allergic reactions to drugs in TOXICOLOGIC PATHOLOGY man, can result in a range of clinicopathological manifestations that include nausea, vomiting, abdominal pain, rash, fever, vasculitis, arthritis, lymphadenopathy, glomerulonephritis and cytopenia (4 1). Such serum sickness-like illnesses comprise the bulk of drug-induced immune-mediated reactions in man and are reported to be responsible for 15% of all adverse drug reactions (1 2). This immunopathy can also occur in our animal models, and most of the preceding comments regarding diagnostic approaches used in conventional safety and toxicity studies apply to these disorders. It is widely accepted, however, that these, as well as data from more focused in vivo and in vitro assays, provide little predictive value for allergic reactions to a drug in man (7, 13) .
Any of the aforementioned findings, in accordance with the medical judgement of the pathologist, may provide indications for further investigation of possible immunotoxicity. More specific tests can be conducted in one or both of the following ways: 1) Further investigations defining the lesion or change as immune-mediated, or ruling out immunopathy, can be conducted by the pathologist. These may be conducted within the original study in which the observations were made, or by means of additional studies designed for this purpose. 2) Specific tests for immune function can be conducted. This option will be discussed in more detail in other papers presented at this meeting.
Candidate drugs known to have a cytoreductive or cytotoxic action, as previously discussed, may not warrant such scrutiny, as immunotoxicity might be assumed. Alternatively, specific testing of such compounds may be undertaken to select from a group of chemicals a compound for development that is relatively "immune-sparing." Like screening tests for myelotoxicity or hepatotoxicity, tests that have predictive value for immunotoxicity could, when indicated, be conducted prior to routine toxicity and safety trials, and could include assays discussed in other papers accompanying this report. Such information would, of course, influence how the pathologist or toxicologist designs the "routine" studies and the decision as to whether or not further testing for immunotoxicity is warranted.
SENSITIVITY
Although a rigorous and systematic delineation of the toxicologic profile is accepted by many scientists in this feld as an appropriate "first tier" from which indications for further specific testing for immunotoxicity may be derived (29,60), this approach poses some serious problems which cannot be ignored. The most controversial of these is the question of sensitivity. Whether all toxicologically significant alterations in immune function will ultimately be expressed, in some way, in our present system of safety evaluation is a question that troubles both liberal and conservative scientists in this field. It is widely acknowledged that biologically significant changes in immune function can occur with little morphologic correlate and remain subclinical until the animal or person is subjected to a particular stress or insult. Furthermore, most safety and toxicity studies are conducted in an environment that is relatively pathogen-free, which limits exposure to viral, bacterial and parasitic organisms. Also problematic is the extent to which the functional reserve of the immune system offers protection against adverse effects.
These problems are not unique to this target organ system, however. Thoughtful toxicologists emphasize that the real toxic potential of a drug or chemical is not fully revealed until the hepatocyte, the nephron, the bone marrow, etc., is stressed by exposure to the agent in question. Moreover, because the immune system profoundly influences many other organ systems and tissues, and because resistance to infection and neoplasia is fundamental, it can be argued that changes in immune function that are toxicologically significant to our animal models will, at some point, be expressed over the course of lifetime carcinogenicity, developmental and other safety and toxicity studies, in which animals are being monitored today with increasing sophistication. This argument is supported by the fact that, beyond the range of idiosyncratic, or species-specific hypersensitivity reactions that dominate the immune-mediated adverse effects in man (41), there are few examples of pharmaceuticals approved for marketing (excluding cytoreductive drugs and compounds intended for immunosuppression or immunomodulation) that have been demonstrably and unexpectedly immunotoxic. We must be careful, however, that this history not make us complacent; as we previously indicated, many pharmaceuticals under development today, including products of the new biotechnology, pose new challenges to the immunotoxicologist, as well as scientists in other fields of toxicology.
CHOICE OF ANIMAL MODELS
Relying on the toxicologic profile routinely generated to express important changes in immune function also poses a problem regarding the choice of animal models. It is well established that animal species vary with regard to both immunobiology and susceptibility to established immunotoxic agents (6, 61) . The problem of species specificity is also not unique to the immune system; nevertheless, it poses special logistical problems when investigating or the result of a drug-associated immune suppression often requires follow-up investigations of immune function or a pathologic finding. It is highly desirable that such studies employ the same animal model (ideally, the same animals) in which the change was observed. Reasons for this include the following: 1) the incidence of the adverse effect may be low (yet toxicologically significant) and not easily reproduced; 2) another species may not be susceptible to the toxic effect; 3) the biologic significance, or consequence, of the change is well-defined in that model; and 4) if the change follows long-term exposure to the drug, reproducing the effect could be costly and impractical. The dog and the rat are the most commonly employed species in toxicity and safety studies; however, they are not well-defined immunologically compared with the mouse, in which immune function can be examined with considerably greater sophistication. Of the former species, the consequences of immune dysfunction can best be determined in the dog. One reason for this is that the clinicopathologic parameters are well-defined and practical to examine. Another is that its relatively large size also makes possible simultaneous or sequential pre-mortem sampling of blood, bone marrow and other tissue and the assessment of mu!-tiple immune parameters in the same animal. Such a combination of clinical and laboratory observations (as well as data on pharmacology and drug metabolism in this species, which are often available) is critical in judging the biologic or toxicologic significance of changes in immune parameters. It is therefore particularly frustrating to the toxicologic pathologist that this species is the least well-defined immunologically. This unfortunate predicament is changing, as several laboratories have recently adapted useful tests for immune function to both the rat (15, 37) and the dog, and are implementing them in toxicity studies. Dr. Krakowka, in an accompanying report, has reviewed applications of tests for immune function in the dog in his laboratory. How other tests have been applied to the dog in our laboratory in toxicity studies is discussed later in this report. Because the dog and the rat are the most common animal models used for toxicity testing in the pharmaceutical industry, and are therefore the species for which we usually have the broadest foundation of information with which to interpret drug-induced changes in immune parameters, toxicologic pathologists should continue to improve our understanding of the immune systems of these species. We emphasize, however that as with most other potential target organ systems, there is no evidence to suggest that any one animal model offers a superior predictive value for drug-induced immunotoxicity in man.
A less critical problem inherent in toxicity and safety studies is the fact that in subacute and chronic studies, where toxicity in general is often most welldefined, cumulative effects may present a misleading immunotoxicologic profile (especially for drugs intended for short-term use in man); animals can adapt to toxic doses or develop tolerance.
Because the sensitivity of routine toxicity and safety studies, regarding detection of immunotoxicity, is uncertain, additional triggers for special testing should be considered. Important among these is the intended use of the candidate drug (the immunotoxic potential of an agent that is designed to treat chronic disease, and will be administered over long periods of time, would be of greater concern than that designed for short-term treatment). A pharmacologic profile that includes immunomodulatory activity, or actions that are known to affect immune function secondarily, might also trigger such efforts. Again, such indications are often not clear cut and are influenced by the judgement of scientists developing the candidate drug. For example, although prostaglandins have profound effects on immune function (20) , not every prostaglandin inhibitor is immunotoxic nor need necessarily be examined specifically for its effect on the immune system. Other indications include a chemical structure similar to compounds known to be immunoactive in the pharmacology laboratory or the clinic.
Finally, we occasionally have the opportunity to investigate important questions regarding the immunopharmacology of a compound, or mechanisms of an adverse effect already associated with similar compounds in man. As we equip our minds and our laboratories for assessing the immunotoxicity of candidate compounds, we should be alert to opportunities unique to an R&D environment for solving other important problems through basic research. We therefore include such opportunities among the indications for employing tests that more specifically define the effects of compounds on the immune system.
The following examples illustrate some of the points we have discussed. at SK&F and other laboratories have shown that, like the injectable gold salts (e.g., gold sodium thiomalate), auranofin affects a variety of immune parameters in man (Table I) . Because the pharmacologic and clinical profiles of this agent and related compounds include immunomodulatory activity, and because the intended use of the drug includes long-term therapy, the immunotoxic potential of auranofin, relative to that of gold sodium thiomalate, was explored. Results of experiments comparing the relative effects on immune parameters of auranofin versus injectable gold salts had previously been published (Table I) (14, 28, 30, 62) . These studies, however, involved in vifro experiments, short-term administration of the drugs to laboratory rodents, or ex vhv studies in patients with rheumatoid arthritis. Thus, in the absence of pre-existing immunopathy such as rheumatoid arthritis, whether the long-term administration of these drugs affected these immune parameters remained an important question.
In a seven-year toxicity study ofauranofin in dogs (Table 11) , clinicopathologic evidence of immunopathy was observed in 4/14 high-dose dogs (which received approximately 30 times the human dose). This included immune thrombocytopenia (3/14), immune hemolytic anemia (211 4), renal amyloidosis (1/14) and hypothyroidism due to severe chronic lymphocytic thyroiditis (111 4). Sequential histologic (Figs. 1-3) , cytologic, serologic and serum biochemical observations were used to characterize these disorders in the affected dogs. Evidence for more than one of these conditions was observed in three of the four affected dogs. Only the immune thrombocytopenia was clearly drug-associated; this immunopathy, which we have described in detail in a previous report (4), was similar to that described in human patients on long-term parenteral chrysotherapy.
Specific tests for immune function were performed on dogs from the auranofin study as well as on dogs from a similar seven-year toxicity study of gold sodium thiomalate (Myochrysine@, Merck Sharp and Dohme, West Point, PA) conducted in parallel ( Table 11 ). The indications for these tests can be summarized as follows: 1) a pharmacologic profile that includes immune-modulating activity; 2) a toxicologic profile that includes possible drugassociated immunopathy; 3) a clinical profile of au- ranofin and other gold compounds that includes treatment-associated changes in immune function; 4) an indication that entails long-term treatment; and 5 ) a unique research opportunity to investigate the effect of long-term chrysotherapy on immune function in the absence of pre-existing immunopathy.
The tests performed are listed in Table 111 . Selection of the tests was influenced by published reports of effects of gold compounds on immune pat
FIG.
3.-ProteinA-colloidalgoldconjugate-stained buffy coat platelet collected from a high-dose dog from the 7-year auranofin study which developed thrombocytopenia after more than 5 years of treatment (4). Increased membrane-bound immunoglobulin, indicated by the clectron-dense conjugate (arrows), suggests that the thrombocytopenia is immune-mediated. (Reprinted with permission from Veterinary Pathology.) x 16,800. TOXICOLOGIC PATHOLOGY rameters in rodents or patients with rheumatoid arthritis (Table I ) and data suggesting that the macrophage is an important potential target for the drug's immune-modulating, and hence therapeutic, effects (22, 23, 50) . Some of these tests were adapted to the dog in our laboratory (56) .
Results of these immune function assays showed no clear drug-associated group changes, relative to the controls, in dogs treated with auranofin or gold sodium thiomalate. One high-dose auranofin-treated dog with nephrotic syndrome secondary to severe renal amyloidosis showed a depression of several parameters of immune function; these changes correlated with a declining creatinine clearance and progressive azotemia. The results suggested either that the parameters selected were unaffected by the gold compounds or that tests employed to measure these aspects of immune function lacked adequate sensitivity to detect the drug effects. Disease modification may have influenced the treatment-associated changes in these parameters reported in patients with rheumatoid arthritis receiving chrysotherapy. This study exemplifies how specific tests for immune function can be employed in a problemdriven fashion within a conventional safety evaluation in a well-defined animal model. EXAMPLE 2: CEFONICID In a 6-month intravenous toxicity study of cefonicid (MonocidB, Smith Kline and French Laboratories, Philadelphia, PA), a second generation cephalosporin antibiotic, anemia, neutropenia, thrombocytopenia and bone marrow depression was observed in up to 50% of dogs receiving high doses (10 to 15 times the human dose) of the drug. The hematologic syndrome was similar to that described in a small percentage of human patients receiving cephalosporin treatment (2,57). In addition, several observations suggested that the toxicologic mechanism included a drug-associated, immune-mediated component. These included signs of hemolysis with autoagglutination (Fig. 4) , increased hemophagocytosis in hematopoietic tissues (Fig. 5) , and a delayed onset of the syndrome, which was substantially shortened on re-exposure to the drug. Similar hematopathology was demonstrated using other cephalosporin antibiotics, including cefazedone (RefosporinB, E. Merck, Darmstadt). In subsequent studies on cefonicid in dogs, an agglutinating red cell antibody was characterized.
Further studies on the mechanism of cephalosporin-induced hematotoxicity in the dog focused on the following possible mechanisms: 1) antibody-mediated cytopenia, 2) changes in bone marrow mi-.croenvironment and 3) suppression of bone marrow stem cell activity. Using a solid-phase radioim- 
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a Adapted to the dog (56).
munoassay employing 1251-staphylococcal protein A, increased red cell-, neutrophil-and platelet-associated immunoglobulin was demonstrated in dogs showing the cefazedone-induced syndrome (5) . In the same model, drug-associated ultrastructural changes in bone marrow, including mitochondria1 damage, proliferation of endosteal bone lining cells, and a maturation arrest in the erythroid and granulocytic series, were defined using scanning and transmission electron microscopy (1 0). Suppression of bone marrow stem cell activity (CFU-E and CFU-GM) was demonstrated (1 1); serum factors were shown to have an inhibitory effect in some affected dogs, suggesting that the suppression may be antibody-mediated. In addition to characterizing the immune-mediated aspects of the syndrome, these studies a) demonstrated that this toxic potential was shared by other cephalosporin antibiotics, b) established the dog as a useful model for studying this important disorder in man, and c) offered new insights on the multiple pathogenetic mechanisms of the syndrome. 
CONCLUSIONS
Screening candidate drugs for an immunotoxic potential poses several practical problems and entails many disadvantages. A more rational approach would be based upon a comprehensive evaluation of immune dysfunction, as determined by observations of immunotoxicity derived initially from the extensive toxicologic evaluation of pharmaceutical compounds. The sensitivity of conventional test systems in expressing toxicologically significant changes in immune function is uncertain. However, by taking full advantage of the substantial data base available on candidate drugs, including the toxicologic profile, to provide indications for specific testing for immunotoxicity, this toxic potential can be explored and thoughtfully evaluated. This problemoriented approach to immunotoxicology calls for a close working relationship among the toxicologic pathologist, the immunologist, the pharmacologist and the clinician.
